By Justin Leverenz, Chief Investment Officer, Developing Markets Equities China is unique among developing markets, not only ...

For all the attention on U.S.-China AI competition, new studies point to China's rapid rise in biotechnology, especially for ...

A dual-track approach has gained momentum for biotech companies as capital markets remain volatile and acquirers become more ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase (WRN) ...

| When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from ...

Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic pulmonary fibrosis ...

MAIA’s Chairman and CEO Vlad Vitoc, M.D., expressed optimism regarding the results, stating, "This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC ...

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate ...

The companies Pathos AI, Taysha Gene Therapies, and Abeona Therapeutics bagged the biggest biotech funding rounds overall in ...

Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, "We are pleased to renew our collaboration ...